Intravenous immunoglobulin for Guillain-Barré syndrome

Retrospective evaluation of Guillain‐Barre syndrome in children: A single‐center experience

“…This was attributed to the shorter duration of IVIG treatment in patients with more severe clinical findings. The duration of IVIG administration was also seen not to affect the long‐term prognosis, which was consistent with the literature 36 …”

Retrospective evaluation of Guillain‐Barre syndrome in children: A single‐center experience

“…This was attributed to the shorter duration of IVIG treatment in patients with more severe clinical findings. The duration of IVIG administration was also seen not to affect the long‐term prognosis, which was consistent with the literature 36 …”

Six‐month prospective study of quality of life in Guillain‐Barre syndrome

“…GDS is the most commonly used disability outcome measure in this disease. 19,20 Our study confirmed that it is sensitive to register changes in GBS during a 6-month period from disease onset. During a 6-month follow-up, we observed significant difference of GDS between each time points indicating a gradual functional recovery.…”

Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study

“…Moreover, the effectiveness of Gamunex (91.3%) was shown to be comparable to PE (84.6%). The risk ratio of Gamunex versus PE was 1.08 (in favor of Gamunex), which was identical to the observed risk ratio from the Cochrane metaanalysis 15 comparing IVIg to PE, further supporting the effectiveness of IVIg in GBS. The success rates of Gamunex were not notably different among subgroups of patients distinguished by age, total Gamunex dose received, or GBS severity and type.…”

Retrospective evaluation of Guillain‐Barre syndrome in children: A single‐center experience

“…This was attributed to the shorter duration of IVIG treatment in patients with more severe clinical findings. The duration of IVIG administration was also seen not to affect the long‐term prognosis, which was consistent with the literature 36 …”

Six‐month prospective study of quality of life in Guillain‐Barre syndrome

“…GDS is the most commonly used disability outcome measure in this disease. 19,20 Our study confirmed that it is sensitive to register changes in GBS during a 6-month period from disease onset. During a 6-month follow-up, we observed significant difference of GDS between each time points indicating a gradual functional recovery.…”

Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study

“…Moreover, the effectiveness of Gamunex (91.3%) was shown to be comparable to PE (84.6%). The risk ratio of Gamunex versus PE was 1.08 (in favor of Gamunex), which was identical to the observed risk ratio from the Cochrane metaanalysis 15 comparing IVIg to PE, further supporting the effectiveness of IVIg in GBS. The success rates of Gamunex were not notably different among subgroups of patients distinguished by age, total Gamunex dose received, or GBS severity and type.…”

Retrospective evaluation of Guillain‐Barre syndrome in children: A single‐center experience

“…This was attributed to the shorter duration of IVIG treatment in patients with more severe clinical findings. The duration of IVIG administration was also seen not to affect the long‐term prognosis, which was consistent with the literature 36 …”

Six‐month prospective study of quality of life in Guillain‐Barre syndrome

“…GDS is the most commonly used disability outcome measure in this disease. 19,20 Our study confirmed that it is sensitive to register changes in GBS during a 6-month period from disease onset. During a 6-month follow-up, we observed significant difference of GDS between each time points indicating a gradual functional recovery.…”

Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study

“…Moreover, the effectiveness of Gamunex (91.3%) was shown to be comparable to PE (84.6%). The risk ratio of Gamunex versus PE was 1.08 (in favor of Gamunex), which was identical to the observed risk ratio from the Cochrane metaanalysis 15 comparing IVIg to PE, further supporting the effectiveness of IVIg in GBS. The success rates of Gamunex were not notably different among subgroups of patients distinguished by age, total Gamunex dose received, or GBS severity and type.…”